Glioblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We report here the detection of the BRAF V600E mutation in a patient with c-GBM and describe the patient's clinical course as well as the results of histopathological analysis.
|
25885250 |
2015 |
Glioblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
This case suggests that the BRAF V600E mutation may be involved in the malignant transformation to glioblastoma.
|
26404554 |
2016 |
Glioblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
These findings suggest that epithelioid GBM may arise from a PXA with a BRAF V600E mutation.
|
24894018 |
2014 |
Glioblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The serine/threonine-protein kinase B-Raf (BRAF) V600E mutation has been found at a high frequency of 54% in epithelioid glioblastomas.
|
26375727 |
2016 |
Glioblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The aim of the current study was to examine BRAF V600E mutations in 20 GBMs, including GBMs with epithelioid features, giant cell GBMs and conventional GBMs.
|
30013630 |
2018 |
Glioblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our data suggest routine screening for BRAF V600E mutations for glioblastomas WHO grade IV below the age of 30, especially in glioblastomas with epithelioid features and in all rhabdoid meningiomas WHO grade III.
|
27350555 |
2016 |
Glioblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we describe a case of systemic metastases of a clonal subpopulation of BRAF V600E mutated glioblastoma in a patient previously treated with surgery, radiation, temozolomide and bevacizumab.
|
29744614 |
2018 |
Glioblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Epithelioid glioblastoma is a recognized glioblastoma variant, recently added to the World Health Organization brain tumor classification, with similar prognosis as the classic variant and B-Raf V600E mutations in 50% of the cases.
|
31258848 |
2019 |
Glioblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Epithelioid GBM with BRAF V600E mutation can be considered a good treatment indication for precision medicine, and this patient-derived cell line should be useful for prediction of the tumor response and clarification of its biological characteristics.
|
31345255 |
2019 |
Glioblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.
|
25581727 |
2015 |
Glioblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity.
|
29105198 |
2018 |
Glioblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutational analyses should be performed on E-GBMs, particularly in all pediatric and young-aged adults, given the potential for BRAF inhibitor therapy in this subset of GBM patients.
|
23552385 |
2013 |
Glioblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutations were identified in only 2 of 71 (2.8%) glioblastoma (GBM) analyzed, including 1 of 9 (11.1%) giant cell GBM (gcGBM).
|
21479234 |
2011 |
Glioblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
An institutional cohort of 105 brain tumors (51 dysembryoplastic neuroepithelial tumors (DNTs), 14 subependymal giant cell astrocytomas (SEGAs), 12 glioblastoma with neuronal marker expression (GBM-N), and 28 pleomorphic xanthoastrocytomas (PXAs)) from 100 patients were investigated for the presence of BRAF(V600E) by direct sequencing.
|
25346165 |
2015 |